Trial intelligence / Profile preview

iPACK block effect on NLR and PLR in knee arthroplasty

NCT06304298Phase 4

Key facts

Status: Completed
Start: Mar 2024
Primary completion: Jan 2025
Countries: 1
Sponsor: Poznan University of Medical Sciences
Modality: Orthosteric Ligands

Drugs: ropivacaine
Conditions: postoperative pain

Overview

Phase 4, randomised, double-blind trial of ropivacaine in postoperative pain (2 arms), sponsored by Poznan University of Medical Sciences. Primary endpoint: Neutrophil-to-lymphocyte ratio. Started Mar 2024; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

Sham blocks
iPACK block with 20ml of 0.9% sodium chloride
iPACK block
iPACK block with 20ml of 0.2% ropivacaine

Who it enrols

Adult patients (20-90 years) scheduled for knee arthroplasty under spinal anesthesia, excluding those with bleeding diathesis, anticoagulant therapy, chronic pain history, multiple trauma, dementia, or infection.

Endpoints

Primary

Neutrophil-to-lymphocyte ratio12 hours after surgery

Secondary

Platelet-to-lymphocyte ratio48 hours after surgery
Neutrophil-to-lymphocyte ratio48 hours after surgery
First need of opiate48 hours after procedure
Opioid Consumption48 hours after surgery
Pain score48 hours after surgery

Beyond the preview

Go deeper on NCT06304298.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06304298.